<DOC>
	<DOCNO>NCT01373931</DOCNO>
	<brief_summary>This study involve single dose 18 mg LY2216684 take 1 2 tablet mouth . The study evaluate effect LY2216684 pharmacokinetics oral contraceptive Ortho CyclenÂ® . This study run approximately 93 day .</brief_summary>
	<brief_title>A Study LY2216684 Healthy Females</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Are overtly healthy female , determine medical history physical examination As possible LY2216684 may cause oral contraceptive ( OC ) tablet less effective usual , subject require addition use double barrier method contraception Screening 2 month post study followup . Additional barrier method contraception may include follow : nonhormonal intrauterine device spermicide ; female condom spermicide ; contraceptive sponge spermicide ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence ( subject report abstinence become sexually active study must agree use additional barrier method contraception ) . The pregnancy test result must negative Screening Checkin Have body weight &gt; 50 kg Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample per protocol Have normal blood pressure pulse rate ( sit position ) determine investigator Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly institutional review board ( IRB ) govern site Are currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product investigational product use study , concurrently enrol type medical research judge scientifically medically compatible study Have know allergy Ortho Cyclen , LY2216684 , related compound Are person previously complete withdrawn study study investigate LY2216684 within 6 month prior Screening Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have history show evidence significant active neuropsychiatric disease history suicide attempt ideation Regular use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus infection ( HIV ) and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Are woman positive pregnancy test woman lactate Intend use overthecounter prescription medication ( acceptable oral contraceptive ( OC ) allow study influenza vaccination ) within 14 day prior dose unless deem acceptable investigator sponsor 's medical monitor Have donate blood 500 mL prior leadin phase Checkin ( Day 1 ) Have average weekly alcohol intake exceed 14 unit per week , unwilling stop alcohol consumption 48 hour prior Checkin clinical research unit ( CRU ) ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) Consume 5 cup coffee ( beverage comparable caffeine content ) per day , habitual basis , subject unwilling adhere study caffeine restriction use tobacco nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior leadin phase Checkin ( Day 1 ) study Have consume grapefruit , starfruit , pomegranate , product contain item 7 day prior enrollment unwilling avoid study Have document suspected history glaucoma Subjects take injectable contraceptive within 12 month enrollment study topical control delivery contraceptive ( patch ) 3 month prior enrollment study The history presence contraindication combine oral contraceptive ( OC ) tablet include thrombosis history thromboembolic disease , recurrent jaundice , acute chronic liver disease , migraine , undiagnosed vaginal bleeding , significant hyperlipidemia , mammary , endometrial , hepatic carcinoma ( know suspect ) Subjects determine unsuitable investigator reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>